Fox News |
Heart, Mini-Stroke Risks From Asthma Drug: FDA
WebMD Sept. 29, 2014 — A safety study done by the maker of the asthma drug omalizumab (Xolair) suggests it poses slightly increased but serious risks for heart attacks and mini-strokes known as TIAs (transient ischemic attacks), the FDA says. Because of … FDA slaps cardiovascular warnings on Roche/Novartis asthma blockbuster Xolair FDA says asthma drug Xolair raises risk of heart, brain problems FDA adds cardiovascular risks to Xolair label for asthma treatment |
View full post on asthma – Google News